ASP Isotopes (ASPI) investor relations material

Strategic initiatives and operational milestones

• Focus on isotope enrichment for nuclear medicine, semiconductors, and nuclear energy, with commercial production targeted within six months and new plant construction planned.

• Four verticals: PET Labs (radioisotopes), stable isotope facilities (Silicon-28, Carbon-14, Ytterbium-176), helium production, and Quantum Leap Energy (nuclear fuels).

• PET Labs achieved over 50% revenue growth in H1, with revenue expected to double by 2026; Alpha Theranostics to enter clinical trials this year.

• Silicon-28, Carbon-14, and Ytterbium-176 facilities in South Africa are being commissioned, with first shipments and commercial production expected in the second half of the year.

• Quantum Leap Energy spinoff targeted for Q3, with S-1 filed and review process ongoing.

Helium asset and market dynamics

• South African helium asset started production, with first shipments expected in September and free cash flow by year-end.

• Asset designated strategic by both South African and U.S. governments, with $750 million in funding secured for phase two.

• Global helium supply crisis driven by outages in Qatar, Russian export controls, and rising demand from semiconductors and rocketry.

• Asset offers high helium concentration, low carbon footprint, and efficient global shipping from South Africa.

• Phase one targets 70 MCF/day helium and 2,500 GJ/day LNG; phase two to expand to 900 MCF/day helium and 34,000 GJ/day LNG.

Financial outlook and contracts

• Phase one expected to generate $27 million in revenue and $11 million gross profit at $600/MCF helium, with upside at higher prices.

• Phase two projected to deliver $370 million in revenue and $300 million gross profit, with production starting in 2030 and full year in 2031.

• Long-term contracts (5–15 years) in place for LNG and helium, with inflation-linked pricing; spot and short-term contracts for isotopes.

• 2031 EBITDA guidance of $300 million, with significant contributions from electronic gases, LNG, helium, and radiopharmaceuticals.